Key Highlights
- $260 million investment for new state-of-the-art production facility in Sejong, South Korea.
- Facility will feature eight production trains and produce tens of metric tons annually.
- Includes cutting-edge peptide R&D facilities and cGMP labs for clinical and commercial production.
- Hiring over 300 employees to support the expansion by late 2026.
- Addresses global demand for small molecules and peptides in life-saving therapies.
Source: Business Wire
Notable Quotes
- “This expansion is a testament to our unwavering dedication to serving the evolving needs of the life sciences industry.” — Joerg Ahlgrimm, CEO at SK pharmteco
- “By expanding our capacity and capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality.” — Yongwoo Park, President, Small Molecule, Asia at SK pharmteco
SoHC's Take
This $260 million investment by SK pharmteco underscores the company’s forward-thinking strategy in addressing the growing global demand for innovative treatments, particularly small molecules and peptides. As the life sciences industry faces ongoing challenges related to manufacturing capacity and regulatory hurdles, SK pharmteco’s new facility in Sejong represents a critical step toward enhancing global supply chain resilience. With the addition of state-of-the-art R&D and production capabilities, SK pharmteco positions itself as a key player in advancing medical breakthroughs and supporting the commercialization of groundbreaking therapies worldwide.
